UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):August 9, 2019
EYEGATE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-36672 | | 98-0443284 |
| (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
| | | |
271 Waverley Oaks Road
Suite 108
Waltham, MA | | 02452 |
| (Address of principal executive offices) | | (Zip Code) |
(781) 788-9043
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | | Trading Symbol(s) | | Name of each exchange on which registered: |
| Common Stock, $0.01 par value | | EYEG | | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.x
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Chief Medical Officer
On August 9, 2019, Barbara Wirostko notified EyeGate Pharmaceuticals, Inc. (the “Company”) of her decision to resign as Chief Medical Officer in order to pursue other interests related to her specialty of glaucoma. Dr. Wirostko’s resignation will be effective as of August 23, 2019 (the “Effective Date”). Dr. Wirostko will continue to serve the Company as a consultant following the Effective Date.
Dr. Wirostko’s decision to depart from the Company does not reflect any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Wirostko for her many contributions and willingness to consult for the Company to help ensure the execution of the clinical studies for the Company’s Ocular Bandage Gel (“OBG”) product and potential future filings with the U.S. Food and Drug Administration.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | EYEGATE PHARMACEUTICALS, INC. |
| | |
| | | |
| | By: | /s/ Stephen From |
| | | Stephen From |
| | | President and Chief Executive Officer |
| | |
| | |
| | Date: August 15, 2019 |
